Latest Biotech News

Krystal Biotech disclosed early clinical findings indicating its gene therapy approach can deliver native cystic fibrosis protein across mutation types and produced signals the company views as...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to bridge venture investors and emerging biotech companies, with the stated goal of accelerating capital...

Aktis Oncology priced an upsized initial public offering that raised $318 million, marking biotech’s first major public debut of 2026. The Boston-based radiopharmaceutical developer sold 17.65...

Eli Lilly agreed to acquire Ventyx Biosciences in a cash deal valued at roughly $1.2 billion to add oral NLRP3 inhibitors to its inflammation portfolio. Lilly said the acquisition will broaden its...

Parabilis Medicines closed a $305 million Series F to accelerate zolucatetide and other Helicon‑platform candidates that target intracellular, historically intractable oncology proteins. The...

Boltz PBC spun out of MIT with a $28 million seed round to commercialize a suite of open, AI‑driven drug discovery models developed at CSAIL. Led by co‑founders from Regina Barzilay’s group, the...

Krystal Biotech disclosed early clinical findings for a mutation‑agnostic gene therapy intended to deliver native protein to cystic fibrosis patients, and the company signaled plans to pursue a...

Orca Bio raised $250 million in financing to support the commercial launch of its T‑cell therapy for complications arising after allogeneic stem cell transplant. The round is intended to fund...

AirNexis Therapeutics closed a $200 million Series A and in‑licensed HSK39004 (AN01) from Haisco to advance a China‑origin PDE3/4 inhibitor for COPD. The deal gives Haisco a 19.9% equity stake and...

Eikon Therapeutics filed for a U.S. initial public offering, positioning its platform and pipeline as an early test of whether recent market optimism can reopen the IPO window for biotech. The...

Illumina appointed former NHGRI director Eric Green as chief medical officer, a strategic hire as the sequencing leader pivots toward clinical applications and healthcare integration. Green will...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to improve engagement between investors and emerging biotech companies and to accelerate capital formation for...

Aktis Oncology priced an upsized initial public offering that raised $318 million, marking the first biopharma IPO of 2026. The Boston-based radiopharmaceutical developer sold 17.65 million shares...

Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion in cash, adding oral NLRP3 inhibitors to Lilly’s inflammation pipeline. Lilly cited Ventyx’s mid‑stage clinical data...

Parabilis Medicines raised $305 million in a Series F financing to advance its corkscrew‑shaped peptide platform against intracellular and previously 'undruggable' protein targets. The round, led...

A team from MIT's CSAIL launched Boltz as a public benefit corporation and closed a $28 million seed round to commercialize open AI models for molecular structure prediction and therapeutic...

Researchers linked to the Baby KJ personalized CRISPR case and Jennifer Doudna launched Aurora Therapeutics with seed backing to develop grouped, mutation‑targeted gene‑editing therapies. Menlo...

Illumina appointed former NHGRI director Eric Green as chief medical officer, signaling a push to lean harder into clinical genomics and precision medicine. Green, who served 16 years at NHGRI,...

EpiBiologics closed a $107 million Series B to advance its EpiTAC protein‑degrader antibody platform and prepare its lead candidate EPI‑326 for first‑in‑human testing. The Bay Area company...

AirNexis Therapeutics raised $200 million in a Series A and acquired exclusive outside‑China rights to Haisco’s PDE3/4 inhibitor for COPD, funding development of AN01. The deal structure includes...